[Adjuvant and neoadjuvant therapy of melanoma].

Abstract

The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.